Exelixis (EXEL) Stock Price

Exelixis Price

NASDAQ·CLOSED
53.03USD-2.94 (-5.39 %)
Market closed

Over the last 19 years Exelixis grew revenue by 18.1% annually, reaching 2.32 B USD. Earnings per share have grown at 11.8% per year over the last 14 years. For Exelixis, the net margin of 33.7% is up versus 16.1% a few years ago. The consensus 12-month price target for Exelixis is 50.49 USD, about 4.8% below where the stock trades today. Of 27 analysts, 15 rate the stock a buy — an overall Buy consensus. The stock trades about 54% above its 52-week low.

Exelixis stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Exelixis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Exelixis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Exelixis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Exelixis Stock Price History
DateExelixis Price
7/31/202653.03 USD
7/30/202655.97 USD
7/29/202656.27 USD
7/27/202656.17 USD
7/23/202655.65 USD
7/22/202654.98 USD
7/21/202656.12 USD
7/20/202655.53 USD
7/17/202655.92 USD
7/16/202655.68 USD
7/15/202655.55 USD
7/14/202655.77 USD
7/13/202655.77 USD
7/10/202656.50 USD
7/9/202657.10 USD
7/8/202656.60 USD
7/7/202657.08 USD
7/6/202655.63 USD
7/2/202655.85 USD
7/1/202653.96 USD
6/30/202654.41 USD
6/29/202654.80 USD
6/26/202654.77 USD
6/25/202653.23 USD
6/24/202652.87 USD
6/23/202651.34 USD
6/22/202651.19 USD
6/18/202651.27 USD
6/17/202652.13 USD
6/16/202652.59 USD
6/15/202652.96 USD
6/12/202653.57 USD
6/11/202653.10 USD
6/10/202653.04 USD
6/9/202652.99 USD
6/8/202651.74 USD
6/5/202652.40 USD
6/4/202651.84 USD
6/3/202650.31 USD
6/2/202648.97 USD
6/1/202649.98 USD
5/29/202650.94 USD
5/28/202652.01 USD
5/27/202650.64 USD
5/26/202650.07 USD
5/22/202649.71 USD
5/21/202649.33 USD
5/20/202649.81 USD
5/19/202648.67 USD
5/18/202649.84 USD
5/15/202650.13 USD
5/14/202651.10 USD
5/13/202651.29 USD
5/12/202649.46 USD
5/11/202649.71 USD
5/8/202648.16 USD
5/7/202646.21 USD
5/6/202648.70 USD
5/5/202644.42 USD
5/4/202644.17 USD
5/1/202643.68 USD
4/30/202644.46 USD
4/29/202644.69 USD
4/28/202644.93 USD
4/27/202644.65 USD
4/24/202644.94 USD
4/23/202646.05 USD
4/22/202646.85 USD
4/21/202645.89 USD
4/20/202643.61 USD
4/17/202644.89 USD
4/16/202644.38 USD
4/15/202644.28 USD
4/14/202645.86 USD
4/13/202644.96 USD
4/10/202644.27 USD
4/9/202645.41 USD
4/8/202644.20 USD
4/7/202643.99 USD
4/6/202643.98 USD
4/2/202644.28 USD
4/1/202644.04 USD
3/31/202642.89 USD
3/30/202641.95 USD
3/27/202641.53 USD
3/26/202642.36 USD
3/25/202642.79 USD
3/24/202641.57 USD
3/23/202641.41 USD
3/20/202641.27 USD
3/19/202641.26 USD
3/18/202641.26 USD
3/17/202641.83 USD
3/16/202641.07 USD
3/13/202641.24 USD
3/12/202641.17 USD
3/11/202641.75 USD
3/10/202641.29 USD
3/9/202642.39 USD
3/6/202641.55 USD
3/5/202641.28 USD
3/4/202641.69 USD
3/3/202640.74 USD
3/2/202641.03 USD
2/27/202644.06 USD
2/26/202644.28 USD
2/25/202644.75 USD
2/24/202645.10 USD
2/23/202644.01 USD
2/20/202643.63 USD
2/19/202644.16 USD
2/18/202644.71 USD
2/17/202644.08 USD
2/13/202643.92 USD
2/12/202642.70 USD
2/11/202642.78 USD
2/10/202642.51 USD
2/9/202643.95 USD
2/6/202643.90 USD
2/5/202642.37 USD
2/4/202642.67 USD
2/3/202642.59 USD
2/2/202642.81 USD
1/30/202641.75 USD
1/29/202642.28 USD
1/28/202642.66 USD
1/27/202643.74 USD
1/26/202643.61 USD
1/23/202644.27 USD
1/22/202644.50 USD
1/21/202644.81 USD
1/20/202643.79 USD
1/16/202643.96 USD
1/15/202645.44 USD
1/14/202645.41 USD
1/13/202644.08 USD
1/12/202643.91 USD
1/9/202644.04 USD
1/8/202644.15 USD
1/7/202646.19 USD
1/6/202643.68 USD
1/5/202642.40 USD
1/2/202643.58 USD
12/31/202543.83 USD
12/30/202544.04 USD
12/29/202545.37 USD
12/26/202546.24 USD
12/24/202546.51 USD
12/23/202546.81 USD
12/22/202546.06 USD
12/19/202544.30 USD
12/18/202542.57 USD
12/17/202542.00 USD
12/16/202541.60 USD
12/15/202541.39 USD
12/12/202540.88 USD
12/11/202541.50 USD
12/10/202541.07 USD
12/9/202541.87 USD
12/8/202542.17 USD
12/5/202544.36 USD
12/4/202544.37 USD
12/3/202544.01 USD
12/2/202543.44 USD
12/1/202543.43 USD
11/28/202544.17 USD
11/26/202544.21 USD
11/25/202543.13 USD
11/24/202542.25 USD
11/21/202542.51 USD
11/20/202541.78 USD
11/19/202542.14 USD
11/18/202542.65 USD
11/17/202542.42 USD
11/14/202541.65 USD
11/13/202542.35 USD
11/12/202543.32 USD
11/11/202542.91 USD
11/10/202541.41 USD
11/7/202541.26 USD
11/6/202540.51 USD
11/5/202540.37 USD
11/4/202539.48 USD
11/3/202538.06 USD
10/31/202538.67 USD
10/30/202539.24 USD
10/29/202539.43 USD
10/28/202540.08 USD
10/27/202539.99 USD
10/24/202539.01 USD
10/23/202538.05 USD
10/22/202536.08 USD
10/21/202536.13 USD
10/20/202534.51 USD
10/17/202539.26 USD
10/16/202539.21 USD
10/15/202540.03 USD
10/14/202539.51 USD
10/13/202538.44 USD
10/10/202538.14 USD
10/9/202538.57 USD
10/8/202538.64 USD
10/7/202539.63 USD
10/6/202540.01 USD
10/3/202540.04 USD
10/2/202541.35 USD
10/1/202541.20 USD
9/30/202541.30 USD
9/29/202540.57 USD
9/28/202540.57 USD
9/25/202539.04 USD
9/24/202538.69 USD
9/23/202539.81 USD
9/22/202539.58 USD
9/19/202540.11 USD
9/18/202540.45 USD
9/17/202540.44 USD
9/16/202538.79 USD
9/15/202539.01 USD
9/12/202539.31 USD
9/11/202539.07 USD
9/10/202537.70 USD
9/9/202538.28 USD
9/8/202537.69 USD
9/5/202537.89 USD
9/4/202537.38 USD
9/3/202536.96 USD
9/2/202537.18 USD
8/29/202537.27 USD
8/28/202537.90 USD
8/27/202538.51 USD
8/26/202538.34 USD
8/25/202537.90 USD
8/22/202538.65 USD
8/21/202538.71 USD
8/20/202537.86 USD
8/19/202537.52 USD
8/18/202537.78 USD
8/15/202538.21 USD
8/14/202538.47 USD
8/13/202538.49 USD
8/12/202537.95 USD
8/11/202537.41 USD
8/8/202537.72 USD
8/7/202537.39 USD
8/6/202537.71 USD
8/5/202537.46 USD
Access this data via the Eulerpool API
Get Free API Key

Exelixis Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.83 B USD
170.89 M USD
207.77 M USD
Jan 1, 2024
2.17 B USD
604.62 M USD
521.27 M USD
Jan 1, 2025
2.32 B USD
872.19 M USD
782.57 M USD
Jan 1, 2026 (e)
2.60 B USD
1.49 B USD
985.43 M USD
Jan 1, 2027 (e)
2.93 B USD
1.69 B USD
1.15 B USD
Jan 1, 2028 (e)
3.24 B USD
1.86 B USD
1.33 B USD
Jan 1, 2029 (e)
3.44 B USD
1.98 B USD
1.38 B USD
Jan 1, 2030 (e)
3.05 B USD
1.75 B USD
1.16 B USD

Exelixis Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 5:28 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.040.190.450.850.970.991.431.611.832.172.322.602.933.243.443.05
48.00416.22136.6588.7213.362.0745.2912.3413.5918.477.0111.9412.9010.506.30-11.47
89.1996.3496.6896.9596.5996.3596.3796.4096.0196.4996.3896.3896.3896.3896.3896.38
0.030.180.440.830.930.951.381.551.762.092.242.502.833.123.322.94
-0.12-0.030.170.440.370.110.290.200.170.600.871.491.691.861.981.75
-327.03-14.6636.5051.3538.1611.1419.9412.489.2927.8637.5957.4557.4757.4757.4657.46
-0.17-0.070.150.690.320.110.230.180.210.520.780.991.151.331.381.16
-36.94-58.58-320.00348.05-53.48-65.42108.11-21.2113.74151.6950.1025.9616.9515.803.67-16.20
227.45301.32313.34312.44315.03319.52323.19323.26313.02281.73281.86281.86281.86281.86281.86281.86
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Exelixis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Exelixis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Exelixis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Exelixis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Exelixis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Exelixis stock margins

The Exelixis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Exelixis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Exelixis.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
96.32 %
19.98 %
16.10 %
Jan 1, 2022
96.41 %
12.51 %
11.31 %
Jan 1, 2023
96.04 %
9.34 %
11.35 %
Jan 1, 2024
96.49 %
27.88 %
24.04 %
Jan 1, 2025
96.39 %
37.59 %
33.73 %
Jan 1, 2026 (e)
96.39 %
57.47 %
37.94 %
Jan 1, 2027 (e)
96.39 %
57.47 %
39.29 %
Jan 1, 2028 (e)
96.39 %
57.47 %
41.19 %

Exelixis Stock Revenue, EBIT, Earnings per Share

The Exelixis earnings per share therefore indicates how much revenue Exelixis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
4.44 USD
0.89 USD
0.71 USD
Jan 1, 2022
4.98 USD
0.62 USD
0.56 USD
Jan 1, 2023
5.85 USD
0.55 USD
0.66 USD
Jan 1, 2024
7.70 USD
2.15 USD
1.85 USD
Jan 1, 2025
8.23 USD
3.09 USD
2.78 USD
Jan 1, 2026 (e)
9.21 USD
5.30 USD
3.50 USD
Jan 1, 2027 (e)
10.40 USD
5.98 USD
4.09 USD
Jan 1, 2028 (e)
11.50 USD
6.61 USD
4.73 USD

Exelixis business model & stock analysis

Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health.

Exelixis SWOT Analysis

Strengths

1. Strong product portfolio: Exelixis Inc offers a diverse range of innovative pharmaceutical products, giving the company a competitive edge in the market.

2. Robust research and development (R&D) capabilities: The company has invested heavily in R&D, allowing them to continuously develop new and improved drugs.

3. Established reputation: Exelixis Inc has built a solid reputation for delivering high-quality products and has gained the trust of healthcare professionals worldwide.

Weaknesses

1. Reliance on key products: The company's revenue heavily relies on a few key products, which could pose a risk if sales decline or face regulatory issues.

2. Limited geographic presence: Exelixis Inc primarily operates in select markets, limiting its potential customer base and growth opportunities.

3. Vulnerability to market competition: Intense competition from rival pharmaceutical companies could impact market share and profitability.

Opportunities

1. Expansion into new markets: Exelixis Inc can explore untapped markets or enter into strategic partnerships to reach a wider customer base.

2. Growing demand for innovative therapies: With rising healthcare needs and advancements in medical science, there is an increasing demand for new and effective treatments.

3. Emerging markets: The company can take advantage of opportunities offered by emerging markets, where healthcare infrastructure and access to medicines are improving.

Threats

1. Stringent regulatory environment: Regulatory changes or delays in obtaining approvals may impact the company's ability to launch new products or expand into new markets.

2. Intellectual property challenges: Exelixis Inc may face patent infringements or challenges, potentially affecting the exclusivity and profitability of its products.

3. Economic uncertainties: Global economic fluctuations, healthcare reforms, or changes in insurance coverage could impact consumer spending on pharmaceuticals.

Exelixis Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Exelixis Employees
Details
Date
Exelixis Employees
Jan 1, 2017
- Employees
Jan 1, 2018
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2025
- Employees
Jan 1, 2026
- Employees

Exelixis Segments

Exelixis Revenue by Segment (1/8)

  • Max

Net product revenues
Collaboration services revenues
License revenues
Details
Date
Net product revenues
Collaboration services revenues
License revenues
Cotellic
Jan 1, 2025
1.81 B USD
8.46 M USD
12.92 M USD
0.00 USD
Jan 1, 2026
2.12 B USD
197.32 M USD
0.00 USD
0.00 USD

Exelixis Revenue by Segment (2/8)

  • Max

Gross product revenues
Total collaboration revenues
Collaboration services revenues
License revenues
Discounts and allowances
Details
Date
Gross product revenues
Net product revenues
Total collaboration revenues
Collaboration services revenues
License revenues
Discounts and allowances
Jan 1, 2025
2.52 B USD
0.00 USD
359.31 M USD
0.00 USD
0.00 USD
-708.85 M USD
Jan 1, 2026
3.01 B USD
0.00 USD
0.00 USD
-948,000.00 USD
20.13 M USD
-889.00 M USD

Exelixis Revenue by Segment (3/8)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Cotellic
Jan 1, 2025
0.00 USD
Jan 1, 2026
0.00 USD

Exelixis Revenue by Segment (4/8)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
CABOMETYX
COMETRIQ
Jan 1, 2025
0.00 USD
0.00 USD
Jan 1, 2026
0.00 USD
0.00 USD

Exelixis Revenue by Segment (5/8)

  • Max

Cotellic
Details
Date
Gross product revenues
License revenues
Research and development service revenues
Cotellic
MINNEBRO
Discounts and allowances
Other collaboration revenues
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
13.60 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2026
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Exelixis Revenue by Segment (6/8)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Net product revenues
Collaboration revenue
MINNEBRO
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2026
0.00 USD
0.00 USD
0.00 USD

Exelixis Revenue by Segment (7/8)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
CABOMETYX
COMETRIQ
Jan 1, 2025
0.00 USD
0.00 USD
Jan 1, 2026
0.00 USD
0.00 USD

Exelixis Revenue by Segment (8/8)

  • Max

Reportable Segment
Details
Date
Reportable Segment
Jan 1, 2025
2.17 B USD
Jan 1, 2026
2.32 B USD

Exelixis Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
Europe
International
Japan
Details
Date
United States
Europe
International
Japan
Jan 1, 2018
632.93 M USD
182.88 M USD
38.02 M USD
0.00 USD
Jan 1, 2020
770.24 M USD
152.77 M USD
0.00 USD
44.76 M USD
Jan 1, 2021
1.09 B USD
302.07 M USD
0.00 USD
43.50 M USD
Jan 1, 2021
752.89 M USD
151.63 M USD
0.00 USD
83.02 M USD
Jan 1, 2022
1.41 B USD
168.59 M USD
0.00 USD
28.73 M USD
Jan 1, 2023
1.65 B USD
144.97 M USD
0.00 USD
39.49 M USD
Jan 1, 2025
1.82 B USD
318.63 M USD
0.00 USD
27.08 M USD
Jan 1, 2026
2.14 B USD
154.17 M USD
0.00 USD
25.59 M USD

Exelixis Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Exelixis historical P/E ratio, EBIT multiple, and P/S ratio

Exelixis annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Exelixis shares outstanding

The number of shares of Exelixis was 281.86 M in 2025. This indicates how many shares Exelixis is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
323.19 M Stocks
Jan 1, 2022
323.26 M Stocks
Jan 1, 2023
313.02 M Stocks
Jan 1, 2024
281.73 M Stocks
Jan 1, 2025
281.86 M Stocks
Jan 1, 2026 (e)
281.86 M Stocks
Jan 1, 2027 (e)
281.86 M Stocks
Jan 1, 2028 (e)
281.86 M Stocks

Current Exelixis forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
5.32 %
Buy
55.56 % (15)
Hold
40.74 % (11)
Sell
3.70 % (1)
12M Price Target
50.49
Last Price
56.06
Currency
USD
12M Return Potential
-9.93 %
LTM Return
0 %

Exelixis Analyst Rating Actions

DateFirmActionRatingReliability
7/23/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight60
7/14/2026
Barclays
Barclays
MaintainedEqual Weight33
7/13/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
7/7/2026
Truist Securities
Truist Securities
MaintainedHold–
7/7/2026
RBC Capital
RBC Capital
MaintainedSector Perform52
7/2/2026
UBS
UBS
MaintainedNeutral51
7/2/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
6/25/2026
Truist Securities
Truist Securities
DowngradeBuyHold–
6/24/2026
Citizens
Citizens
MaintainedMarket Outperform–
5/7/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Exelixis Earnings Calls

2025

Exelixis Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/5/20260.81USD-647.52 MUSD-2026 Q2
5/6/20260.74USD-617.42 MUSD-2026 Q1
2/10/20260.78USD-616.02 MUSD-2025 Q4
4/30/20240.20USD-493.85 MUSD-2024 Q1
2/5/20240.23USD-499.47 MUSD-2023 Q4
8/1/20230.24USD-450.16 MUSD-2023 Q2
5/2/20230.24USD-433.57 MUSD-2023 Q1
11/1/20220.19USD-409.10 MUSD-2022 Q3
8/9/20220.19USD-396.78 MUSD-2022 Q2
5/10/20220.15USD-378.05 MUSD-2022 Q1
...

EESG©

Eulerpool ESG Scorecard© for the Exelixis stock

78/100
53
Environment
99
Social
81
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees51
Percentage of women in management—
Percentage of Asian employees43
Share of Asian management—
Percentage of Hispanic/Latino employees6
Hispano/Latino Management share—
Percentage of Black employees6
Black Management Share—
Percentage of white employees41
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Exelixis shareholder structure

% Name
10.93308%
BLACKROCK, INC.
BLACKROCK, INC.
9.12316%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
9.02174%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.57345%
Farallon Capital Management, L.L.C.
Farallon Capital Management, L.L.C.
4.93646%
Renaissance Technologies LLC
Renaissance Technologies LLC
4.87009%
RENAISSANCE TECHNOLOGIES LLC
RENAISSANCE TECHNOLOGIES LLC
...

Exelixis Beneficial Ownership Filings (SEC 13D/G)

Free Float
81.3%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
10.20%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
7.20%
William Seybold
William Seybold
SEC ↗
7.20%
Varun N. Gehani
Varun N. Gehani
SEC ↗
7.20%
Thomas G. Roberts, Jr.
Thomas G. Roberts, Jr.
SEC ↗
5.90%
Wehrly, Mark C.
Wehrly, Mark C.
SEC ↗
5.90%
Warren, John R.
Warren, John R.
SEC ↗
5.90%
Spokes, Andrew J. M.
Spokes, Andrew J. M.
SEC ↗
5.90%
Short Daniel S.
Short Daniel S.
SEC ↗
5.90%
Saito Edric C.
Saito Edric C.
SEC ↗
5.90%
Roberts, Jr., Thomas G.
Roberts, Jr., Thomas G.
SEC ↗

Exelixis Executives and Management Board

16 members · avg. age 63 · 31 % women

MM

Dr. Michael Morrissey (64)

President, Chief Executive Officer, Director · since 2000

12.73 M USD

Management

CS

Mr. Christopher Senner (57)

Chief Financial Officer, Executive Vice President

4.68 M USD
PH

Mr. Patrick Haley (49)

Executive Vice President - Commercial

4.65 M USD
JH

Mr. Jeffrey Hessekiel (56)

Executive Vice President

3.74 M USD
DA

Dr. Dana Aftab (62)

Executive Vice President - Research and Development

3.62 M USD
BH

Dr. Brenda Hefti

General Counsel

–

Board of Directors

MB

Dr. Mary Beckerle (70)

Independent Director

1.16 M USD
SE

Dr. S. Gail Eckhardt (67)

Independent Director

1.16 M USD
SP

Dr. Stelios Papadopoulos (76)

Independent Chairman of the Board, Co-Founder

542,596.00 USD
MF

Dr. Maria Freire (71)

Independent Director

511,596.00 USD
JW

Mr. Jack Wyszomierski (69)

Independent Director

510,596.00 USD
JS

Ms. Julie Smith (54)

Independent Director

507,800.00 USD

Frequently asked questions about Exelixis

The business model of Exelixis Inc is focused on the development, commercialization, and discovery of therapies for the treatment of cancer. The company primarily engages in the research and development of small molecule therapies, targeting specific pathways that contribute to the growth and spread of cancer cells. Exelixis Inc aims to bring innovative and effective cancer treatments to patients by leveraging its expertise in drug discovery and development. The company collaborates with various partners, including pharmaceutical companies and research institutions, to advance its pipeline of potential oncology treatments.

Exelixis Inc is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Exelixis Inc in the market are Bristol-Myers Squibb Co., Merck & Co. Inc., and Pfizer Inc.

Exelixis Inc. is a biotechnology company founded in 1994, headquartered in Alameda, California. The company focuses on the discovery, development, and commercialization of novel therapies to treat cancer and other serious diseases. With a strong emphasis on precision medicine, Exelixis aims to improve patients' lives through targeted therapies. Throughout its history, Exelixis has made significant advancements in drug development and has brought several innovative medicines to market. Notably, the company's flagship product, CABOMETYX® (cabozantinib), has been approved for the treatment of various cancers. Exelixis continues to invest in research and development, collaborating with partners to expand its pipeline and deliver new treatments to patients worldwide.

Exelixis Inc, a renowned biotechnology company, has achieved significant milestones in its journey. Notably, the company secured a major breakthrough with the FDA approval of its flagship product, Cabometyx, for the treatment of advanced renal cell carcinoma. Additionally, Exelixis Inc successfully expanded Cabometyx's indications to include advanced hepatocellular carcinoma, solid tumors, and differentiated thyroid cancer. The company also witnessed positive clinical trial results, demonstrating the efficacy of Cabometyx in several cancer types. Exelixis Inc's continuous dedication to research and development has propelled it to become a leading name in the pharmaceutical industry, revolutionizing cancer treatment with groundbreaking therapies.

Exelixis Inc is primarily present in the United States, focusing on developing and commercializing innovative medicines. Based in Alameda, California, the company's operations extend across the nation. Exelixis Inc has established strategic partnerships and collaborations worldwide, engaging in research and development efforts with renowned institutions and organizations globally.

Exelixis Inc represents values of innovation, collaboration, and commitment to improving patients' lives. With a focus on discovering and developing small molecule drugs, the company strives for scientific excellence in bringing groundbreaking therapies to market. Exelixis Inc is dedicated to advancing the field of oncology with their portfolio of targeted medicines, addressing the unmet needs of cancer patients. By fostering partnerships and working closely with the medical community, Exelixis Inc believes in the power of collaboration to drive meaningful progress in the fight against cancer. Note: This answer contains 99 words.

Analysts currently set an average price target of 48.11 USD for the Exelixis stock (median: 50.49 USD), implying -14.2 % versus the latest price. The consensus is based on 27 analyst ratings.

Exelixis Analyst Price Targets 2026

27 analysts currently rate the Exelixis stock: 15 recommend buying, 11 holding and 1 selling. For 2026, analysts expect Exelixis to generate revenue of 2.60 B USD and earnings per share of 3.50 USD.

Exelixis Analyst Price Targets 2026

Converted at the current exchange rate, the Exelixis share trades at 46.01 EUR (53.03 USD).

The Exelixis share (EXEL) is listed on 8 stock exchanges, including: NASDAQ (EXEL), XETRA (EX9.DE), Frankfurt (EX9.F), München (EX9.MU), Düsseldorf (EX9.DU), London (0IJO.L), London (0IJO.L), SIX (Zürich) (EX9.SW).

Exelixis Inc. is a biopharmaceutical company specializing in the research, development, and marketing of drugs for the treatment of cancer. The company is headquartered in Alameda, California, USA. The business model of Exelixis is based on three pillars: research and development, product marketing and licensing, and collaborations and partnerships with other pharmaceutical companies. Research and development involve the discovery of new compounds and therapies for the treatment of cancer. Exelixis specializes in identifying signaling pathways that are important for the survival and growth of tumor cells. The company has an extensive pipeline of cancer drugs in various stages of development. The most well-known product of Exelixis is Cabozantinib, which is approved for the treatment of kidney cancer and thyroid cancer. Exelixis markets its products through its own sales organization in the USA and through partnerships with other companies worldwide. The company aims to expand its presence in the USA and other countries to increase revenue and profits. Exelixis also works closely with other pharmaceutical companies to acquire licenses for new technologies and products, and to form partnerships for the joint development and marketing of drugs. These collaborations can help accelerate Exelixis' research and development efforts and bring its products to market faster. In summary, the business model of Exelixis Inc. is based on the research, development, and marketing of cancer drugs. The company engages in extensive research and development, has a pipeline of drugs in various stages of development, and collaborates with other companies to acquire new technologies and products and form partnerships for the joint development and marketing of drugs. Exelixis aims to expand its presence in the US and international markets to increase its revenue and profit.

The expected revenue of Exelixis is 2.60 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Exelixis is 985.43 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Exelixis is currently 15.17. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Exelixis stock.

The price-to-sales ratio (P/S) of Exelixis is currently 5.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Exelixis stock.

The Eulerpool Quality Score for Exelixis is 6/10.

The ISIN of Exelixis is US30161Q1040. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Exelixis is 936718. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Exelixis is EXEL. The ticker symbol is used to trade Exelixis shares on the stock exchange.

Exelixis paid dividends every year for the past 0 years.

Exelixis is assigned to the 'Health' sector.

The dividends of Exelixis are distributed in USD.

All fundamentals and in-depth analysis of Exelixis

Our stock analysis for Exelixis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exelixis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Exelixis Stock
Exelixis Revenue→
Exelixis Stock
Exelixis Net Income→
Exelixis Stock
Exelixis P/E→
Exelixis Stock
Exelixis P/S→
Exelixis Stock
Exelixis EBIT→
Exelixis Stock
Exelixis Dividend→
Exelixis Stock
Exelixis Directors Dealings→
Exelixis Stock
Exelixis Stocks→
Exelixis Stock
Exelixis Market capitalization→
Exelixis Stock
Exelixis Debt→
Exelixis Stock
Exelixis Liabilities→
Exelixis Stock
Exelixis Equity→
Exelixis Stock
Exelixis AAQS→
Exelixis Stock
Exelixis Employees→
Exelixis Stock
Exelixis ROE→
Exelixis Stock
Exelixis ROA→
Exelixis Stock
Exelixis ROCE→
Exelixis Stock
Exelixis News→
Exelixis Stock
Exelixis Analyst Price Targets→

Health Stocks

ExicureExcelsior Medical CoeXoZymesExcelsior BiopharmaExpreS2ion Biotech HoldingExagenExtendicareExact Therapeutics ASEyebright Medical Technology (Beijing) CoeWeLL CoEyeGate PharmaceuticalsEvotec SE ADRAll Stocks A–Z →